Welcome to our dedicated page for Medicus Pharma Ltd. SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. SEC filings document material-event reporting for a clinical-stage life sciences and biotechnology company incorporated in Ontario. The filings identify the company's one-segment operating model and record capital-structure activity involving common shares, shelf registration statements, at-the-market offering arrangements and a standby equity purchase agreement.
Recent Form 8-K disclosures also cover unregistered equity sales, debenture financing with subsidiary guaranties, debt repayment mechanics, amendments to equity distribution agreements and listing-compliance notices. These filings frame the company's financing arrangements, governance obligations, securities registration activity and exchange-status disclosures.
Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus receives an exclusive, sublicensable, worldwide license to develop, manufacture and commercialize CD228V and related products for all human diseases.
As consideration, Medicus paid Pfizer a $12.0 million non-refundable upfront payment and must pay an additional $15.0 million on the first anniversary of the effective date. Pfizer paid Medicus a $2.0 million non-refundable Development Funding Payment to be used solely for CD228V development activities. Pfizer is eligible for development, regulatory and sales-based milestone payments that in aggregate exceed $1.0 billion, plus tiered low double-digit royalties on annual Net Sales.
Medicus retains sole authority and bears the costs for development, regulatory approval, manufacturing and commercialization, while Pfizer keeps ownership of the patent rights and an economic interest via milestones, royalties and specified participation in change-of-control, sublicensing or other strategic transactions. Pfizer also holds an option to fund all or part of development from and after the first pivotal trial, subject to a separate definitive agreement.
Medicus Pharma Ltd. reported a larger loss and higher spending for the quarter and six months ended June 30, 2026, while significantly increasing its cash through new debt and equity financings. The company remains a clinical-stage biotech with no product revenue and focuses on its SkinJect microneedle cancer patch and Teverelix programs.
Total assets were $27.1 million, including cash and cash equivalents of $15.2 million and restricted cash of $10.0 million, against total liabilities of $28.8 million, resulting in a shareholders’ deficit of $1.7 million. The six‑month net loss widened to $20.7 million from $11.3 million a year earlier, driven by higher general and administrative expenses of $12.5 million and research and development expenses of $7.6 million, including increased Teverelix trial activity and stock‑based compensation.
Operating cash use was $16.0 million over six months, funded by $32.4 million of financing inflows: $22.0 million in secured promissory notes, $12.4 million from an at‑the‑market program and $4.1 million from a standby equity purchase agreement, partly offset by debenture repayment. Management discloses substantial doubt about the company’s ability to continue as a going concern without further capital and notes a Nasdaq minimum bid‑price deficiency.
Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as independent auditor for the 2026 fiscal year, with 28,308,860 votes for and 756,378 votes withheld.
All nine director nominees were elected, each receiving about 15.1 million votes for and 13.5 million broker non-votes. Shareholders also approved a special resolution authorizing the board to implement a consolidation of the company’s common shares at a ratio of up to 50 pre-consolidation shares for each post-consolidation share, if the board determines such a step is necessary or desirable.
Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith received a grant of stock options covering 200,000 common shares on June 3, 2026. The options have an exercise price of $0.36 per share, vest quarterly in four equal installments over one year, and expire on June 3, 2031. Following this grant, he holds 200,000 options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. According to the footnote, the award vests quarterly in four equal installments over one year, meaning the director earns 12,500 options every quarter until fully vested. Following this grant, she holds 50,000 stock options directly, providing equity-based compensation linked to the company’s future share performance.
Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and were granted as a compensation award at no upfront cost. They are scheduled to vest quarterly in four equal installments over one year, giving Raju the right, once vested, to buy Medicus Pharma common shares at the fixed exercise price until the options expire in 2031.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options covering 250,000 Common Shares. The options carry an exercise price of $0.36 per share and expire on June 3, 2031. According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this award, Faisal holds 250,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, she holds options for 50,000 shares directly.
According to the terms, the option grant was made on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. This is a compensation-related award, not an open-market purchase or sale of shares.
Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares. The option carries an exercise price of $0.36 per share, was granted on June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. The option expires on June 3, 2031, and represents a compensation-related award rather than an open-market share purchase or sale.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, he holds stock options for 50,000 shares. According to the grant terms, the options vest quarterly in four equal installments over one year, meaning the award becomes exercisable gradually rather than all at once.